SCHEMBL3312656

SCHEMBL3312656

CC(=O)N1CCN(c2cccc(N)c2C)CC1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.72
CASP6 P55212 1/20 0.51
GFER P55789 1/20 0.51
LMNA P02545 5/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
MAPT P10636 4/20 0.50
NCF1 P14598 2/20 0.49
TSHR P16473 2/20 0.48
KDM4E B2RXH2 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
ALOX15 P16050 1/20 0.48
HSD17B10 Q99714 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 3/20 0.47
GLA P06280 1/20 0.45
GAA P10253 1/20 0.45
HTR6 P50406 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3315976 0.86 ALDH1A1 (0.60) ALDH1A1CASP6GFERLMNAMEN1
SCHEMBL23124284 0.86 ALDH1A1 (0.60) ALDH1A1CASP6GFERLMNAMEN1
SCHEMBL29795641 0.86 ALDH1A1 (0.60) ALDH1A1CASP6GFERLMNAMEN1
SCHEMBL12890006 0.85 ADRA2C (0.61) ALDH1A1CASP6GFERMEN1KMT2A
SCHEMBL21084414 0.84 ALDH1A1 (1.00) ALDH1A1LMNAMEN1KMT2AMAPT
SCHEMBL29462025 0.84 ALDH1A1 (1.00) ALDH1A1LMNAMEN1KMT2AMAPT
SCHEMBL10377137 0.83 ALDH1A1 (0.57) ALDH1A1CASP6GFERLMNAMEN1
SCHEMBL17738756 0.81 ALDH1A1 (0.55) ALDH1A1CASP6GFERLMNAMEN1
SCHEMBL23123479 0.79 ALDH1A1 (0.52) ALDH1A1CASP6GFERLMNAMEN1
SCHEMBL9905007 0.78 KEAP1 (0.62) ALDH1A1LMNAMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010049731-A1 PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2010-05-06 WO disclosed
US-20100105655-A1 NOVEL COMPOUNDS 515 ASTRAZENECA AB 2010-04-29 US disclosed
US-20100105655-A1 NOVEL COMPOUNDS 515 ASTRAZENECA AB 2010-04-29 US disclosed
US-20100105655-A1 NOVEL COMPOUNDS 515 ASTRAZENECA AB 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105655-A1 NOVEL COMPOUNDS 515 TYMS, ABCG2, UMPS ALDH1A1 649/4885CASP6 2309/4885GFER 4798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.